(MFC) Manulife Financial - Overview
Stock: Insurance, Annuities, Wealth Management, Asset Management, Banking
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.01% |
| Yield on Cost 5y | 8.32% |
| Yield CAGR 5y | 7.59% |
| Payout Consistency | 95.3% |
| Payout Ratio | 37.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.3% |
| Relative Tail Risk | -4.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.02 |
| Alpha | 16.70 |
| Character TTM | |
|---|---|
| Beta | 1.017 |
| Beta Downside | 1.192 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.75% |
| CAGR/Max DD | 1.86 |
Description: MFC Manulife Financial January 29, 2026
Manulife Financial Corp (NYSE:MFC) operates globally across the United States, Canada, Asia and other regions, delivering a broad suite of financial products through three primary segments: Wealth & Asset Management, Insurance & Annuity Products, and Corporate & Other (including reinsurance, timberland, and agricultural investments). The firm’s distribution network spans agency-based channels, independent brokers, banks, and direct-to-consumer platforms.
In its latest quarter (Q4 2023), Manulife reported net income of **$1.2 billion**, earnings per share of **$2.84**, and total assets under management (AUM) of **~$1.3 trillion**. The Canadian life-insurance combined ratio improved to **92.5%**, while the U.S. wealth-management division grew assets by **5.2% YoY**, driven by higher client inflows into retirement and advisory solutions.
Key drivers shaping Manulife’s outlook include: (1) a persistently low-interest-rate environment that compresses traditional life-insurance margins, prompting the company to accelerate its shift toward fee-based wealth management and annuity products; (2) demographic aging in North America and Asia, which is expanding demand for long-term care and guaranteed-income annuities; and (3) continued growth in Asian markets, where Manulife’s insurance penetration is rising faster than the regional GDP growth rate of **≈5%**.
For a deeper quantitative dive into Manulife’s valuation metrics and scenario analysis, you might find ValueRay’s data platform useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 5.91b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.30 > 1.0 |
| NWC/Revenue: -30.75% < 20% (prev 48.30%; Δ -79.05% < -1%) |
| CFO/TA 0.03 > 3% & CFO 30.63b > Net Income 5.91b |
| Net Debt (-12.40b) to EBITDA (7.33b): -1.69 < 3 |
| Current Ratio: 0.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.70b) vs 12m ago -4.44% < -2% |
| Gross Margin: 19.18% > 18% (prev 0.82%; Δ 1835 % > 0.5%) |
| Asset Turnover: 7.24% > 50% (prev 4.84%; Δ 2.40% > 0%) |
| Interest Coverage Ratio: 5.73 > 6 (EBITDA TTM 7.33b / Interest Expense TTM 1.54b) |
Altman Z'' -0.02
| A: -0.02 (Total Current Assets 25.79b - Total Current Liabilities 47.83b) / Total Assets 1026.68b |
| B: 0.00 (Retained Earnings 5.09b / Total Assets 1026.68b) |
| C: 0.01 (EBIT TTM 8.85b / Avg Total Assets 989.66b) |
| D: 0.05 (Book Value of Equity 43.86b / Total Liabilities 973.69b) |
| Altman-Z'' Score: -0.02 = B |
What is the price of MFC shares?
Over the past week, the price has changed by -0.18%, over one month by +1.71%, over three months by +15.68% and over the past year by +31.92%.
Is MFC a buy, sell or hold?
- StrongBuy: 3
- Buy: 5
- Hold: 4
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the MFC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.9 | -13.6% |
| Analysts Target Price | 32.9 | -13.6% |
| ValueRay Target Price | 49.5 | 30.1% |
MFC Fundamental Data Overview January 31, 2026
P/E Trailing = 16.7509
P/E Forward = 11.5075
P/S = 2.0237
P/B = 1.9625
P/EG = 0.9202
Revenue TTM = 71.70b CAD
EBIT TTM = 8.85b CAD
EBITDA TTM = 7.33b CAD
Long Term Debt = 13.43b CAD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 13.43b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -12.40b CAD (from netDebt column, last quarter)
Enterprise Value = 75.93b CAD (88.34b + Debt 13.43b - CCE 25.83b)
Interest Coverage Ratio = 5.73 (Ebit TTM 8.85b / Interest Expense TTM 1.54b)
EV/FCF = 2.48x (Enterprise Value 75.93b / FCF TTM 30.63b)
FCF Yield = 40.33% (FCF TTM 30.63b / Enterprise Value 75.93b)
FCF Margin = 42.72% (FCF TTM 30.63b / Revenue TTM 71.70b)
Net Margin = 8.24% (Net Income TTM 5.91b / Revenue TTM 71.70b)
Gross Margin = 19.18% ((Revenue TTM 71.70b - Cost of Revenue TTM 57.95b) / Revenue TTM)
Gross Margin QoQ = 22.24% (prev 9.14%)
Tobins Q-Ratio = 0.07 (Enterprise Value 75.93b / Total Assets 1026.68b)
Interest Expense / Debt = 2.89% (Interest Expense 388.0m / Debt 13.43b)
Taxrate = 13.91% (310.0m / 2.23b)
NOPAT = 7.62b (EBIT 8.85b * (1 - 13.91%))
Current Ratio = 0.54 (Total Current Assets 25.79b / Total Current Liabilities 47.83b)
Debt / Equity = 0.26 (Debt 13.43b / totalStockholderEquity, last quarter 51.44b)
Debt / EBITDA = -1.69 (Net Debt -12.40b / EBITDA 7.33b)
Debt / FCF = -0.41 (Net Debt -12.40b / FCF TTM 30.63b)
Total Stockholder Equity = 51.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.60% (Net Income 5.91b / Total Assets 1026.68b)
RoE = 11.54% (Net Income TTM 5.91b / Total Stockholder Equity 51.15b)
RoCE = 13.70% (EBIT 8.85b / Capital Employed (Equity 51.15b + L.T.Debt 13.43b))
RoIC = 13.08% (NOPAT 7.62b / Invested Capital 58.25b)
WACC = 8.71% (E(88.34b)/V(101.77b) * Re(9.66%) + D(13.43b)/V(101.77b) * Rd(2.89%) * (1-Tc(0.14)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.88%
[DCF Debug] Terminal Value 78.62% ; FCFF base≈28.59b ; Y1≈34.44b ; Y5≈55.51b
Fair Price DCF = 498.1 (EV 822.99b - Net Debt -12.40b = Equity 835.40b / Shares 1.68b; r=8.71% [WACC]; 5y FCF grow 21.84% → 2.90% )
EPS Correlation: -2.89 | EPS CAGR: 8.99% | SUE: 1.14 | # QB: 1
Revenue Correlation: 38.58 | Revenue CAGR: -5.15% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.10 | Chg30d=+0.011 | Revisions Net=+0 | Analysts=7
EPS next Year (2026-12-31): EPS=4.54 | Chg30d=+0.041 | Revisions Net=+6 | Growth EPS=+9.4% | Growth Revenue=+3.2%